STRADVISION Announces Next Phase of Cloud-Driven Innovation in Collaboration with AWS
- Head of Data Innovation Center presents STRADVISION's next roadmap at AWS re:Invent SEOUL, South Korea, Dec. 9, 2025 /PRNewswire/ -- STRADVISION, a global leader in AI-based vision perception technology for vehicles, today announced its...
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement – – Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes – – Favorable safety...
Autocrypt Announces Product Release of Post-Quantum PKI Product, Pioneering PQC-enabled Solutions for Automotive OEMs
SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Leading automotive cybersecurity solutions provider AUTOCRYPT announced on December 8, 2025, the launch of "AutoCrypt PKI-Vehicles," a new next-generation Public Key Infrastructure (PKI) solution...
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product...
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance The Phase 1 ragistomig study achieved its...
TraceLink Announces 2025 Corporate Grant Recipients Driving Global Community Impact
Through this annual program, TraceLink champions global health equity, community resilience, and shared purpose Summary TraceLink announced the eight global nonprofit recipients of its 2025 corporate grant program, supporting organizations in the...
Global Fitness Leader Anytime Fitness Accelerates Asia Expansion with New Regional Agents for Taiwan
TAIPEI, Dec. 2, 2025 /PRNewswire/ -- Anytime Fitness, the world's largest and fastest-growing fitness franchise, continues its momentum across Asia with significant new developments. With more than 5,600 clubs across 40 countries and on all seven...
FIT KING Announces Official Collaboration With Christian Guzman, Highlighting Authentic Recovery in His Training Lifestyle
NEW YORK, Dec. 1, 2025 /PRNewswire/ -- FIT KING, the smart-recovery brand known for helping athletes and everyday fitness enthusiasts feel and perform better, is proud to officially announce its collaboration with Christian Guzman—athlete,...
Zeekr Group Announces November 2025 Delivery Update
HANGZHOU, China, Dec. 1, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new energy vehicle group, today announced its delivery results for November 2025. In...